Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 11/20 | 0.59 |
| ▸ | CDK2 | P24941 | 3/20 | 0.57 |
| ▸ | BCL6 | P41182 | 1/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.43 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 5/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13998583 | 0.82 | GSK3B (0.49) | CDK2 | |
| SCHEMBL30279842 | 0.81 | CSNK2A1 (0.58) | CSNK2A1CDK2KDM4DCSNK2A2 | |
| SCHEMBL33377976 | 0.79 | CDK2 (0.42) | CSNK2A1CDK2 | |
| SCHEMBL30279917 | 0.79 | CDK2 (0.57) | CSNK2A1CDK2BCL6MAPKAPK2KDM4D | |
| SCHEMBL19742549 | 0.79 | CDK2 (0.57) | CSNK2A1CDK2BCL6MAPKAPK2KDM4D | |
| SCHEMBL33377998 | 0.78 | GSK3B (0.40) | CSNK2A1CDK2MAPKAPK2 | |
| SCHEMBL19742795 | 0.76 | CDK2 (0.50) | CSNK2A1CDK2BCL6MAPKAPK2CSNK2A2 | |
| SCHEMBL28421875 | 0.75 | CSNK2A1 (0.55) | CSNK2A1CDK2BCL6 | |
| SCHEMBL13998581 | 0.75 | KCNN3 (0.53) | CDK2 | |
| SCHEMBL15288383 | 0.74 | CDK2 (0.61) | CSNK2A1CDK2KDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109562111-B | CK2 inhibitors, compositions and methods thereof | 北极星药业股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-3474855-B1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS INC (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3474855-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | Polaris Pharmaceuticals, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| US-10227344-B2 | CK2 inhibitors, compositions and methods thereof | POLARIS PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170369489-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS | 2017-12-28 | — | — | US | disclosed |
| WO-2017223432-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369489-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | CSNK1A1, CSNK2A1, CSNK2A3 | CSNK2A1 2/4885CDK2 14/4885BCL6 2482/4885 |
| US-10227344-B2 | CK2 inhibitors, compositions and methods thereof | CSNK1A1, CSNK2A1, CSNK2A3 | CSNK2A1 2/4885CDK2 14/4885BCL6 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.